LUMO

Lumos Pharma Inc.

Price

return (12m)

p/e

0.00

p/bv

0.00

DIVIDEND YIELD

0.00%

LUMO price

Lumos Pharma

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment LUMO

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals LUMO

Valuation

P/E

0.00

Sector -4.26

Industry -4.26

P/BV

0.00

Sector 2.11

Industry 2.11

P/Revenue (PSR)

Sector 2.08

Industry 2.08

EV/EBITDA

1.77

Sector -546.19

Industry -546.19

EV/EBIT

1.77

Sector -37.31

Industry -37.31

P/EBITDA

Sector -50.76

Industry -50.76

P/EBIT

Sector -39.62

Industry -39.62

P/Total Assets

Sector 1.25

Industry 1.25

P/Net Current Assets

0.00

Sector -5.47

Industry -5.47

P/Working Capital

0.00

Sector -1.10

Industry -1.10

EPS

-4.37

Sector -1.94

Industry -1.94

BVPS

0.61

Sector 1.89

Industry 1.89

Efficiency

Gross Margin

100.00%

Sector 38.90%

Industry 38.90%

EBITDA Margin

-1,046.58%

Sector -13,872.56%

Industry -13,872.56%

EBIT Margin

-1,046.58%

Sector -4,253,834.43%

Industry -4,253,834.43%

Operating Margin

-100.00%

Sector -36.74%

Industry -36.74%

Net Profit Margins

-100.00%

Sector -37.51%

Industry -37.51%

Asset Turnover

0.04

Sector 0.03

Industry 0.03

Profitability

ROE

-711.20%

Sector -61.50%

Industry -61.50%

ROA

-200.00%

Sector -63.85%

Industry -63.85%

ROIC

-942.34%

Sector -498.30%

Industry -498.30%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

2.66

Sector 2.89

Industry 2.89

Net Debt / EBITDA

1.77

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

1.77

Sector -10.24

Industry -10.24

Net Debt / Equity

-2.75

Sector -0.60

Industry -0.60

Gross Debt / Equity

0.00

Sector -0.83

Industry -0.83

Equity/Assets

0.28

Sector 0.43

Industry 0.43

Liabilities/Assets

0.72

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

119.26%

Sector -

Industry -

5Y Earnings CAGR

2.79%

Sector -

Industry -

Fundamentals LUMO

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
LUMO Lumos Pharma Inc.	$0.00	-	0.00%	0.00	0.00	-711.20%	-100.00%
JNJ Johnson & Johnson	$266.50	55.29%	1.93%	31.09	7.70	24.76%	21.48%
PFE Pfizer Inc.	$27.87	21.03%	6.26%	35.86	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$256.91	27.42%	2.58%	74.16	-78.93	-106.44%	9.81%
NVO Novo Nordisk A/S	$45.62	-14.65%	3.95%	11.47	6.09	53.11%	35.32%
MRK Merck & Co. Inc.	$147.77	82.61%	2.24%	116.78	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$161.98	3.71%	1.93%	24.59	5.10	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$66.29	45.78%	3.73%	14.81	6.16	41.55%	18.85%
ZTS Zoetis Inc.	$76.84	-49.43%	2.67%	12.20	10.25	84.02%	27.77%
REGN Regeneron Pharmaceuticals Inc.	$792.43	37.47%	0.44%	19.71	2.69	13.65%	27.86%
AMGN Amgen Inc.	$432.42	55.55%	2.22%	27.25	20.39	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$105.00	43.48%	0.00%	30.73	88.55	288.14%	24.86%
MCK McKesson Corporation	$897.16	31.93%	0.38%	19.60	-26.88	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$542.40	39.41%	0.00%	31.57	6.87	21.76%	35.00%
CAH Cardinal Health Inc.	$235.19	59.60%	0.88%	35.20	-20.39	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$39.29	3.26%	0.00%	12.32	2.23	18.14%	18.89%
BIIB Biogen Inc.	$217.24	59.31%	0.00%	38.68	1.71	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

LUMO Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Lumos Pharma

Lumos Pharma Inc.

Average Investor10 user rating

4.0 (0 people)

United States

27 years

Founded: 1999

2011

Time since IPO - 15 years

32

Employees

Lumos Pharma Inc. (United States) is listed on the Nasdaq and has a market capitalization of $-, with shareholders equity totaling $4.91 million.

The company employs approximately 32 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Lumos Pharma Inc. reported $2.21 million in revenue, generating net income of $-34.92 million.

Key financial metrics include a P/E ratio of 0.00, a price-to-book (P/B) ratio of 0.00, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker LUMO.

Market cap

Net worth

$4.91 million

$4,910,000.00

Assets

$17.46 million

$17,460,000.00

Total Shares Outstanding

8.00 million

8,000,000

Average Daily Trading Volume

$99.00 Thousand

$99,001.38

Sector

Health Care

Industry

Biotechnology

LUMO

LUMO revenue and profits

Financial Results LUMO

DRAG THE FRAME TO SEE MORE DATA

LUMO cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$897.16 31,33% (12M)

P/E

19.60

0.38%

ROE

-137.16%

P/BV

-26.88

CAH - Cardinal Health

$235.19 60,10% (12M)

P/E

35.20

0.88%

ROE

-57.93%

P/BV

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12M)

P/E

31.09

1.93%

ROE

24.76%

P/BV

7.70

ABBV - AbbVie

$256.91 26,00% (12M)

P/E

74.16

2.58%

ROE

-106.44%

P/BV

-78.93

MRK - Merck & Co.

$147.77 82,50% (12M)

P/E

116.78

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$161.98 3,46% (12M)

P/E

24.59

1.93%

ROE

20.74%

P/BV

5.10

PFE - Pfizer

$27.87 22,54% (12M)

P/E

35.86

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$897.16 31,33% (12 M)

P/L

19.60

0.38%

ROE

-137.16%

P/VP

-26.88

CAH - Cardinal Health

$235.19 60,10% (12 M)

P/L

35.20

0.88%

ROE

-57.93%

P/VP

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12 M)

P/L

31.09

1.93%

ROE

24.76%

P/VP

7.70

ABBV - AbbVie

$256.91 26,00% (12 M)

P/L

74.16

2.58%

ROE

-106.44%

P/VP

-78.93

MRK - Merck & Co.

$147.77 82,50% (12 M)

P/L

116.78

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$161.98 3,46% (12 M)

P/L

24.59

1.93%

ROE

20.74%

P/VP

5.10

PFE - Pfizer

$27.87 22,54% (12 M)

P/L

35.86

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Lumos Pharma (LUMO) today?

A cotação de Lumos Pharma (LUMO) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Lumos Pharma (LUMO) iniciou o ano negociando na casa dos US$ 0.00 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Lumos Pharma (LUMO) e dados de ações do Ibovespa e mercados internacionais.

Quando Lumos Pharma (LUMO) paga dividendos?

Lumos Pharma (LUMO) não distribuiu dividendos no último ano.

Is Lumos Pharma (LUMO) a good investment?

Atualmente, Lumos Pharma (LUMO) está cotada a US$ 0.00, com um P/L de 0.00, representando um desvio de -32,465% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Lumos Pharma (LUMO) stock?

Investir em ações de Lumos Pharma (LUMO) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Lumos Pharma (LUMO) yield today?

A rentabilidade de Lumos Pharma (LUMO) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Lumos Pharma (LUMO) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

LUMO

Lumos Pharma Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment LUMO

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING LUMO WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Lumos Pharma

Lumos Pharma Inc.

United States

27 years

2011

32

PROFIT X PRICE LUMO

Financial Results LUMO

LUMO cash flow

Asset, Revenue and Profit Growth - LUMO

LUMO balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions